Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- PIRS
- Price
- 13.60
- Stock movement down
- -2.53 (-15.69%)
- Company name
- Pieris Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 17.96M
- Ent value
- 2.85M
- Price/Sales
- 13.28
- Price/Book
- 1.10
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -11.57%
- 1 year return
- 21.43%
- 3 year return
- -62.29%
- 5 year return
- -45.45%
- 10 year return
- -
Last updated: 2025-04-12
DIVIDENDS
PIRS does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 13.28 |
| Price to Book | 1.10 |
| EV to Sales | 2.11 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 1.32M |
| EPS (TTM) | -12.09 |
| FCF per share (TTM) | -21.22 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 1.35M |
| Gross profit (TTM) | -3.82M |
| Operating income (TTM) | -18.10M |
| Net income (TTM) | -15.95M |
| EPS (TTM) | -12.09 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | -282.77% |
| Operating margin (TTM) | -1338.54% |
| Profit margin (TTM) | -1179.96% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 19.36M |
| Net receivables | 879.00K |
| Total current assets | 20.52M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 20.52M |
| Accounts payable | 801.00K |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 4.25M |
| Total liabilities | 4.25M |
| Shareholder's equity | 16.27M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -28.00M |
| Capital expenditures (TTM) | 26.00K |
| Free cash flow (TTM) | -28.01M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -98.06% |
| Return on Assets | -77.74% |
| Return on Invested Capital | -98.06% |
| Cash Return on Invested Capital | -172.19% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 15.01 |
| Daily high | 15.35 |
| Daily low | 13.26 |
| Daily Volume | 52K |
| All-time high | 756.00 |
| 1y analyst estimate | 7.00 |
| Beta | 0.66 |
| EPS (TTM) | -12.09 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 13 May 2025 |
Downside potential
Loading...
Downside potential data
| PIRS | S&P500 | |
| Current price drop from All-time high | -98.20% | -0.59% |
| Highest price drop | -99.14% | -56.47% |
| Date of highest drop | 11 Jul 2024 | 9 Mar 2009 |
| Avg drop from high | -61.77% | -11.07% |
| Avg time to new high | 60 days | 12 days |
| Max time to new high | 1721 days | 1805 days |
COMPANY DETAILS
Marketcap
17.96M
Marketcap category
Small-cap
Description
Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.
Employees
46
Website
Investor relations
-
SEC filings
CEO
Stephen S. Yoder
Country
USA
City
Boston
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner